Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3

NCT03001310 is registered in ClinicalTrials.gov with MeiraGTx UK II Ltd as lead sponsor.

NCT NCT03001310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03001310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
Lead sponsor
MeiraGTx UK II Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
January 16, 2017
Completion date
October 25, 2019
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

achromatopsia